Last reviewed · How we verify
RNK05047
At a glance
| Generic name | RNK05047 |
|---|---|
| Sponsor | Ranok Therapeutics (Hangzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RNK05047 CI brief — competitive landscape report
- RNK05047 updates RSS · CI watch RSS
- Ranok Therapeutics (Hangzhou) Co., Ltd. portfolio CI